Technology in Cancer Research & Treatment (Aug 2022)

Dosimetric Effects of Differences in Multi-Leaf Collimator Speed on SBRT-VMAT for Central Lung Cancer Patients

  • Masahide Saito PhD,
  • Takafumi Komiyama MD, PhD,
  • Kan Marino MD,
  • Shinichi Aoki MD,
  • Mitsuhiko Oguri MD,
  • Takashi Yamada MD,
  • Naoki Sano PhD,
  • Hidekazu Suzuki RTT,
  • Koji Ueda RTT,
  • Hiroshi Onishi MD, PhD

DOI
https://doi.org/10.1177/15330338221119752
Journal volume & issue
Vol. 21

Abstract

Read online

Purpose: We aimed to investigate the effects of different multi-leaf collimator (MLC) speed constraints in volumetric modulated radiotherapy (VMAT) on the robustness of treatment plans for central lung cancer patients. Method and Materials: Twenty patients with central lung tumor who underwent stereotactic body radiotherapy (SBRT) with the VMAT technique at our hospital were included in this retrospective study. The reference plans were created with 3 different MLC speed constraints (Plan A: 0.1 cm/deg., Plan B: 0.3 cm/deg., and Plan C: 0.5 cm/deg.) with a 50-Gy/8Fr, planning target volume (PTV) D 95% prescription. In each of these plans, setup errors from 1 to 5 mm were intentionally added in the direction of the central organ at 1-mm intervals (300 plans [20 cases × 3 MLC speeds × 5 error plans] were created in total). Each plan was then calculated by the same beam conditions as each reference plan. The actual average MLC speed and dose difference between the reference plan and the error-added plan were then calculated and compared among the 3 MLC speeds. Results: In the reference plans, the actual average MLC speeds were 0.25 ± 0.04, 0.34 ± 0.07, and 0.39 ± 0.12 cm/deg. for Plan A, Plan B, and Plan C, respectively ( P < .05). For PTV and OARs, many dose indices tended to improve as the MLC speed increased, while no significant differences were observed among the 3 MLC speed constraints. However, in assessments of robustness, no significant differences in dose difference were observed among the 3 MLC speed constraints for most of the indices. Conclusions: When necessary, increasing the MLC speed constraint with a priority on improving the quality of the dose distribution is an acceptable approach for central lung cancer patients.